Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Ratner

Showing results (11-20 of 87) with videos related to

Pageof 9
Sort By:
Current Diabetes Reports|January 6, 2011
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?Shannon D Sullivan, Robert E Ratner
Current Diabetes Reports|November 2, 2006
Pramlintide: A new tool in diabetes managementLaura L Want, Robert E Ratner
Diabetes Care|September 23, 2020
Metformin Should Be Used to Treat Prediabetes in Selected IndividualsWilliam H Herman, Robert E Ratner
Diabetes Spectrum : a Publication of the American Diabetes Association|December 5, 2018
Metformin and Type 2 Diabetes PreventionVanita R Aroda, Robert E Ratner
Endocrinology and Metabolism Clinics of North America|March 9, 2005
Novel pharmacologic agents for type 2 diabetesGabriel I Uwaifo, Robert E Ratner
The American Journal of Cardiology|February 20, 2007
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular riskGabriel I Uwaifo, Robert E Ratner
Diabetes Care|December 21, 2013
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving!William T Cefalu, Robert E Ratner
Current Diabetes Reports|September 10, 2008
Combination pharmacotherapy with incretins: what works best and when?Rebecca K Over, Robert E Ratner
Diabetes & Vascular Disease Research|October 2, 2007
Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetesRobert E Ratner, Shamik Parikh, Conrad Tou, et al.
Diabetes/Metabolism Research and Reviews|July 24, 2009
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)Kathleen M Dungan, John B Buse, Robert E Ratner
Pageof 9

Showing results (11-20 of 87) with videos related to

Sort By:
Pageof 9
Current Diabetes Reports|January 6, 2011
Should the metabolic syndrome patient with prediabetes be offered pharmacotherapy?Shannon D Sullivan, Robert E Ratner
Current Diabetes Reports|November 2, 2006
Pramlintide: A new tool in diabetes managementLaura L Want, Robert E Ratner
Diabetes Care|September 23, 2020
Metformin Should Be Used to Treat Prediabetes in Selected IndividualsWilliam H Herman, Robert E Ratner
Diabetes Spectrum : a Publication of the American Diabetes Association|December 5, 2018
Metformin and Type 2 Diabetes PreventionVanita R Aroda, Robert E Ratner
Endocrinology and Metabolism Clinics of North America|March 9, 2005
Novel pharmacologic agents for type 2 diabetesGabriel I Uwaifo, Robert E Ratner
The American Journal of Cardiology|February 20, 2007
Differential effects of oral hypoglycemic agents on glucose control and cardiovascular riskGabriel I Uwaifo, Robert E Ratner
Diabetes Care|December 21, 2013
The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: the "gift" that keeps on giving!William T Cefalu, Robert E Ratner
Current Diabetes Reports|September 10, 2008
Combination pharmacotherapy with incretins: what works best and when?Rebecca K Over, Robert E Ratner
Diabetes & Vascular Disease Research|October 2, 2007
Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetesRobert E Ratner, Shamik Parikh, Conrad Tou, et al.
Diabetes/Metabolism Research and Reviews|July 24, 2009
Effects of therapy in type 1 and type 2 diabetes mellitus with a peptide derived from islet neogenesis associated protein (INGAP)Kathleen M Dungan, John B Buse, Robert E Ratner
Pageof 9